D. E. Shaw & Co., Inc. Cytosorbents Corp Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CTSO
# of Institutions
57Shares Held
16.7MCall Options Held
15.4KPut Options Held
0-
Avenir Corp Washington, DC2.98MShares$2.71 Million0.45% of portfolio
-
Skylands Capital, LLC2.76MShares$2.51 Million0.6% of portfolio
-
Granahan Investment Management, LLC Waltham, MA2.09MShares$1.91 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$1.77 Million0.0% of portfolio
-
Neuberger Berman Group LLC New York, NY1.78MShares$1.62 Million0.0% of portfolio
About Cytosorbents Corp
- Ticker CTSO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 43,577,400
- Market Cap $39.7M
- Description
- Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...